Nitric-Oxide Releasing Molecules : A New Class of Drugs with Several Major Indications
J. L. Burgaud, J. P. Riffaud and P. Del Soldato
Affiliation: NicOx, Gaia II, 2455 route desDolines, B.P. 313, 06906 Sophia-Antipolis-cedex, France
Nitric oxide (NO) deficiency has been implicated in many pathological and physiological processes within the mammalian body providing a plausible biologic basis for the use of NO replacement therapy in these conditions. Exogenous NO sources may hopefully constitute a powerful way to supplement NO when the body cannot generate enough for normal biological functions. This theory has opened up the possibility of designing new drugs that are capable of delivering NO into tissues and the bloodstream in a sustained and controlled manner. This objective has been reached by grafting an organic nitrate structure onto existing molecules with various spacers such as aliphatic or aromatic chain, with different degree of complexity. This approach has led to the synthesis of several new chemical entities in various pharmacological classes, whose profile seems to challenge the parent drug not only on the basis of new pharmacological properties but also on a better toxicological and safety profile. In this article, general aspects on NO and NO donors are reviewed. Major focus is placed upon recent developments of novel NO donors, NO releasing device(s) as well as innovative improvements to conventional NO donors. Several examples are given in some important therapeutic indications such as cardiovascular diseases (NO-aspirin), pain and inflammation (NO-paracetamol), osteoporosis and urinary incontinence (NO flurbiprofen with aliphatic spacer), Alzheimers disease (NO-flurbiprofen with anti-oxidant spacer), respiratory disorders (NO-steroids).
Keywords: Nitric-Oxide Releasing Molecules, iNOs (inducible NO synthase), Rationale, Bronchodilation, NO-flurbiprofen
Rights & PermissionsPrintExport